Georgia Signed a Major Medical Cannabis Expansion. The Doctors Who Tried to Kill It Didn’t Have the Science On Their Side.

When Georgia Gov. Brian Kemp signed Senate Bill 220 into law on May 12, he expanded the state’s medical cannabis program in ways patients had been waiting years for: more flexible THC and CBD ratios, access to vaporized products and concentrates, and a possession limit that finally accounts for the reality of managing a chronic condition.

A coalition of physicians had asked him to do the opposite.

The letter — authored by psychiatrist Dr. Karen Drexler and co-signed by Dr. Elizabeth McCord, among others — urged Kemp to veto the “Putting Georgia’s Patients First Act,” warning of catastrophic health risks and characterizing the bill as a backdoor for dangerous, unregulated drug use. It made national rounds in the days before Kemp’s decision.

The claims don’t hold up.

What the Law Actually Does

SB 220 expands Georgia’s existing medical cannabis program, which already required physician authorization and patient registration through a state registry. The new law doesn’t change who qualifies — it changes what registered patients can access.

Vaporized cannabis products and concentrates are now permitted. The possession limit has been set at 12,000 milligrams of THC. Physicians retain authority over patient guidance and treatment plans.

For Shannon Cloud, whose 20-year-old daughter has experienced seizures her entire life and is registered in Georgia’s program, the law represents something concrete: the flexibility for her daughter’s doctors to find a THC-to-CBD ratio that actually works.

“It allows more flexibility for patients and doctors to access what’s really going to work for them,” Cloud told WABE, “taking away the really tight restrictions.”

“No Demonstrated Safety or Benefit” — The Claim That Doesn’t Hold

The most sweeping assertion in the physicians’ letter was that vaporized cannabis has “no demonstrated safety or benefit for any medical condition.” The letter offered no citations.

That framing runs counter to a body of published clinical literature. A 2024 peer-reviewed study in Cannabis and Cannabinoid Research, developed by physicians at the University of British Columbia and the University of Toronto, examined vaporization as a medical delivery method and concluded it is appropriate for patients requiring fast-acting administration, with vapor inhalers presenting among the lowest safety risk profiles available. A meta-analysis of 15 randomized controlled trials found patients using cannabinoids were significantly more likely to achieve meaningful pain reduction than those who did not. The American College of Physicians has published clinical best-practice guidance on cannabis for chronic pain management.

The letter also cited increased heart attack risk. A University of Colorado study analyzing nearly 1.3 million hospital records found the opposite: cannabis consumers were less likely to go into shock after a cardiac event and less likely to die from cardiac complications. The research landscape is genuinely complex — but the letter’s characterization doesn’t reflect it.

The 1,700 Joints Framing

The letter’s most viral line was the claim that SB 220’s 12,000-milligram possession limit is equivalent to “more than 1,700 marijuana joints.” The math is technically derived from real numbers — it assumes an average joint contains about seven milligrams of THC and treats the possession ceiling as a consumption figure.

The problem is that a possession limit isn’t a dose. It’s the maximum a registered patient can have on hand at one time — not what they’re expected to use in a day or a sitting. Patients managing multiple sclerosis, Parkinson’s, PTSD, or intractable chronic pain often need a reliable supply on hand to avoid repeated dispensary trips. That’s standard practice in every functioning state medical program. By the same logic, a Costco bottle of extra-strength acetaminophen could be framed as containing enough Tylenol to harm 200,000 people.

Personal Anecdote vs. Population Data

Dr. Drexler told WSB-TV that her advocacy was shaped by personal experience: her husband’s uncle, a long-term cannabis user, developed what she characterized as cannabis-induced psychosis in his fifties. She described her conviction as a psychiatrist that his schizophrenia was cannabis-caused.

The link between cannabis and psychosis risk in certain populations — particularly adolescents and those with genetic predispositions — is documented in the scientific literature and worth taking seriously. What that literature doesn’t support is applying that risk profile wholesale to a supervised medical program serving registered adults with serious conditions. German research has also found CBD may have therapeutic potential for schizophrenia specifically — a nuance the letter elides entirely.

Where It Stands

Kemp signed the bill. Georgia patients now have broader access than they did two weeks ago. The physicians’ letter, uncontested in most news coverage at the time, was more a reflection of familiar opposition patterns than a scientifically grounded argument.

The same playbook — alarming numbers stripped of context, anecdote standing in for data, sweeping claims without citations — has appeared in cannabis policy fights across the South for years. In Georgia, it didn’t work. That may be the more notable headline.